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Abstract  
Background 
Discussion whether intravenous tPA or mechanical thrombectomy is the ideal choice for 
treatment of acute ischemic strokes has been debated around the medical community for last 
three decades. However still, after several clinical trials, it is still unclear if one is superior to the 
other. 
Methods 
This meta-analysis pooled several different results from studies revolving around treatment of 
acute ischemic stroke. The goal of this paper was to evaluate whether previous clinical trials 
favoring mechanical thrombectomy had sufficient research to prove it is superior to treatment 
with tPA in reducing long-term morbidity. Primary outcomes measured were the modified 
Rankin scales at 90 days in evaluation of long-term morbidity. 
Results 
Sixteen different studies were evaluated, six trials evaluating tPA efficacy and ten trials 
evaluating mechanical thrombectomy efficacy. Only two out of 6 tPA studies showed positive 
benefit, and seven out of ten mechanical thrombectomy studies showed positive benefit.  
Conclusion 
It is difficult to determine if mechanical thrombectomy is superior to tPA management due to 
several confounders and possible study bias in majority of studies showing positive results in 
mechanical thrombectomy patients. For example, the majority of positive mechanical 
thrombectomy studies and the most common confounder were the studies being stopped early. 
which are then susceptible to bias. More studies will need to be conducted, and fully completed, 
in order to determine if there is positive benefit over tPA. 
Introduction  
 There has been much debate surrounding the topic of management for acute ischemic stroke 
(AIS) patients over the recent decades. The primary therapies debated are whether standard of 
care using tissue plasminogen activator (tPA) management, either alone or in conjunction with 
direct mechanical thrombectomy (DMT) is superior than direct mechanical thrombectomy 
surgery for reducing long term morbidity. Several studies suggest that mechanical thrombectomy 
reduced stroke severity, post-stroke morbidity, and improved revascularization rates compared to 
treatment with tPA alone for the anterior intracranial circulation, the more common major 
intracerebral vessel impacted by AIS 1. However, several other studies suggest that it is unclear 
whether or not direct mechanical thrombectomy has added benefit with or without tPA 
management for improving post-stroke outcomes.  
 According to American Heart Association (AHA), every 40 seconds, someone in the United 
States has a stroke. That statistic accounts for an incidence of about 795,000 people that suffer 
from a new or recurrent stroke each year.  Strokes account for the 4th highest cause of death and 
the number one cause of morbidity in the United States, where ischemic strokes account for 
about 87% of all strokes 2. These statistics prove the importance and relevance of proper 
management of this condition in order to reduce both morbidity and mortality.  
 The management of stroke is dependent on the patient’s symptom presentation, as well as time 
and medical institution sensitive. This is important to discuss given that there are important risks 
to managing strokes with tPA and/or DMT. For example, tPA has an extensive list of 
contraindications including prior stroke in previous 3 months, suspicion of subarachnoid 
hemorrhage, history of previous intracranial hemorrhage, or any active bleeding just to list a few. 
On the other hand, DMT has a higher risk of symptomatic intracerebral hemorrhage after the 
procedure, where the risk factors for this adverse outcome of the procedure are co-morbidities 
such as advanced age, high blood glucose, more severe stroke, and pre-existing computerized 
tomography (CT) changes 3. However, the overall goal of treatment of stroke is minimize time to 
reperfusion in order to prevent further ischemic brain damage, so it is important to determine 
what treatment will be beneficial for each patient subgroups while minimizing adverse outcomes 
within these groups. 
  The goal of this paper is to explore the most common treatments for ischemic strokes of the 
major cerebral arterial circulation. Furthermore, this paper will aim to determine which treatment 
is most beneficial for patients for reducing morbidity as measured by the modified Rankin Scale 
(mRS). 
Background (Literature Review)   
Intravenous thrombolytics, the standard treatment of acute ischemic stroke  
 Intravenous thrombolytics, including tissue plasminogen activator (tPA) and tenectaplase 
(TNKase), has had a long-standing role in the medical community and is considered the “gold 
standard” in treatment of AIS. The use of thrombolytics dates back to the 1950’s, however was 
not FDA approved until 1996 due to the lack of strong evidence of benefits outweighing the 
risks, primarily intracranial hemorrhaging, over that 40-year period 4. It is well known that the 
National Institute of Neurological Disorders and Stroke (NINDS) II trial is the primary study that 
provided evidence that use of thrombolytics are beneficial in the treatment of AIS. The current 
gold standard of care for treatment of AIS is treatment with IV thrombolytics within 4.5 hours of 
symptom onset. The following section will explain the thrombolytics mechanism of action, along 
with background literature of studies that have evaluated thrombolytics in treatment of AIS.  
 Before discussing studies surrounding thrombolytic medication treatment of AIS, it would be 
appropriate to provide background information about the mechanism of action itself. Since the 
majority of studies use tissue plasminogen activator (tPA) as the primary thrombolytic drug, we 
will focus on this drug for this discussion. Thrombolytics are serine protease enzymes that cleave 
peptide bonds in proteins. It’s primary mechanism of action works by catalyzing the conversion 
of plasminogen to plasmin, which is the primary enzyme in dissolving formed clots. This is the 
reason the drug is known as a “clot buster” and holds the primary interest of drug choice for 
patients with occlusions due to thrombus, such as AIS 5. 
 Given the relevance of the 1996 NINDS trial and its significant impact on the treatment of AIS 
with IV thrombolytics, it would be appropriate to summarize the significance of this clinical trial 
within this literature review. During the time before the NINDS trial, promising results from 
previous pilot studies from IV thrombolytics increased curiosity to further explore this drug for 
specific treatment of AIS. However, given the evidence of increased risk of intracranial 
hemorrhaging (ICH) from several of these studies, this large, randomized, double-blind trial was 
conducted to determine if the benefits outweigh the risks (ICH) for treatment of AIS. The study 
had two parts; part one (NINDS-I) measured changes in neurological deficits 24 hours after the 
onset of stroke as a measure of tPA using the National Institutes of Health stroke scale (NIHSS) 
and part two (NINDS-II) used four different scales, including the Barthel index, modified Rankin 
scale, Glascow outcome scale, and NIHSS, to measure the different aspects of recovery sustained 
at 90 days. Part one measured “early improvement”, including complete resolution or 
improvement from baseline determined as a 4 or more-point increase on the NIHSS. Part two 
measured all patients using the aforementioned four outcome measurement tools at 90 days. 
Patients were then grouped by timeframes including 0 to 90 minutes, 91 to 180 minutes, and 0 to 
180 minutes after the onset of stroke for both parts. Safety endpoints included intracranial 
hemorrhage (ICH), death or other serious adverse effects and were screened using CT scans at 24 
hours, 7 to 10 days following onset of stroke, or symptoms suggestive of ICH. Eligibility for 
participation included clearly defined time marker for stroke onset, clearly measureable deficit 
using NHISS, and no evidence of intracranial hemorrhage on noncontrast CT scan. NINDS-I had 
a total of 291 patients enrolled and NINDS-II had a total of 333 patients enrolled. 
Contraindications to randomization included head trauma within 3 months, major surgery within 
the last 14 days, history of intracranial hemorrhage, systolic blood pressure above 185mmHg or 
diastolic blood pressure above 110mmHg, rapidly improving symptoms, symptoms of 
hemorrhage including subarachnoid, GI, or urinary tract within the previous 21 days, had a 
seizure with symptom onset, or patients taking anticoagulants within 48 hours on stroke onset 6. 
The results of this study can be further explored in the discussion section of this paper. 
 Other studies studying thrombolytics have tried to determine whether there is benefit of 
thrombolytic therapy within different timeframes of administration. There were several studies 
conducted shortly after the NINDS trial evaluating different timeframes of the efficacy of 
thrombolytics following the onset of symptoms. The European Cooperative Acute Stroke Study 
(ECASS) conducted three, the ECASS 1, ECASS 2, and ECASS 3 trials in 1995, 1998, and 
2008, respectively. Other studies that looked at timeframe includes the Alteplase Thrombolysis 
for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS), ATLANTIS A and 
ATLANTIS B trials. The ATLANTIS trials, however, were essentially the same trial split 
between modifications mid-trial due to safety concerns. These details will be discussed below.  
 ECASS-I evaluated 620 patients with signs of acute ischemic changes on noncontrast CT and 
were randomized to receive 1.1 mg/kg of rt-PA (alteplase) or placebo within 0-6 hours of onset 
of symptoms. The primary outcomes were evaluated with the Barthel Index and modified Rankin 
scale at 90 days, with secondary outcomes including a combined Barthel Index and Rankin scale, 
Scandinavian Stroke Scale at 90 days and 30-day mortality. Tertiary outcomes included early 
neurologic recovery. The results of this study can be further explored in the discussion section of 
this paper 7. 
 ECASS-II evaluated 800 patients in Europe, Australia, and New Zealand with early ischemic 
signs on noncontrast CT without signs of major infarction. Patients were stratified for time for 
symptom onset of either 0 to 3 hours or 3-6 hours.    Patients were randomly assigned 0.9mg/kg 
rt-PA alteplase or placebo, resulting in 409 and 391 patients, respectively. The primary outcome 
was a modified Rankin scale at 90 days dichotomized for a favorable outcome of score 0-1 vs 
unfavorable outcome of score 2-6. The results of this study can be further explored in the 
discussion section of this paper 8. 
 ECASS-III was a randomized, double-blind, parallel-group trial that evaluated 821 patients 
around multiple centers in Europe to determine if there were beneficial effects of administering 
tPA in patients with AIS between 3 and 4.5 hours after symptom onset. Patients were evaluated 
clinically with noncontrast CT scan for signs of early AIS and excluded if CT showed signs of 
ICH or major infarction. Once inclusion criteria were met, patients were randomly assigned in 
1:1 double-blind fashion to receive either 0.9mg/kg IV tPA or placebo. The primary outcome 
measurement used the mRS at 90 days to evaluate for favorable outcome, defined as a score of 0 
or 1 vs unfavorable outcome of score 2-6. Safety endpoints included symptomatic ICH, death 
and other serious adverse effects 9. The results of this study will be further explored in the 
discussion section of this paper. 
 ATLANTIS A trial was a randomized, double-blind trial that began in August 1991 and again 
evaluated the efficacy and safety of intravenous rtPA for 142 patients with AIS within 6 hours of 
onset. The study consisted of a randomized, double-blind administration of rtPA for patients 
aged 18-80 years old with clearly defined time marker for stroke onset, clearly measureable 
deficit using NHISS, and no evidence of intracranial hemorrhage on noncontrast CT scan, 
similar to the NINDS trial criteria. The intervention group was given of 0.9mg/kg IV rtPA split 
between a 10% IV bolus over the first 1-2 minutes followed by the remaining delivered by 
infusion over the next 1 hour. The primary efficacy outcomes of this study measured as “good 
outcomes” were a 4 or more point decrease on the NIHSS scale at 24 hours and 30 days, as well 
as infarct volume measured by noncontrast CT scan at day 30 at 24+/- 6 hours and at 30+/-7 
days. The secondary outcomes measured were by mortality, Barthel Index and Modified Rankin 
scale at 30 and 90 days. Safety parameters were measured by the blinded independent data safety 
monitoring board (DMSB), which measured overall mortality, asymptomatic intracranial 
hemorrhaging (ICH), symptomatic ICH, fatal ICH, and other serious adverse effects on an 
ongoing basis during the study. The results of this study can be further explored in the discussion 
section of this paper 10. 
 ATLANTIS B trial was a randomized, double-blind, multicenter, placebo-controlled 
clinical trial conducted between 1993 and 1998, further evaluating a more efficacious timeframe 
for administering rtPA. This was part of the same ATLANTIS trial mentioned above, however 
due to safety concerns for patients receiving rtPA >6 hours, the investigators modified the study 
to evaluate the specific time of rtPA resulting in the ATLANTIS “B” trial we discuss here. The 
study inclusion criteria are the same as the ATLANTIS A trial mentioned above. The total 
amount of patients enrolled was 613 between both parts of the study. The intervention group was 
given of 0.9mg/kg IV rtPA split between a 10% IV bolus over the first 1-2 minutes followed by 
the remaining delivered by infusion over the next 1 hour. The outcomes of this trial were the 
same as the ATLANTIS A trial. ATLANTIS B trial, however, heavily focused on safety 
measurements, starting at baseline and monitored closely through 90 days. Neurologic symptoms 
and hemorrhaging symptoms were evaluated by the NIHSS scale at baseline, 120 minutes, 24 
hours, and 7, 30 and 90 days. Barthel Index, Modified Rankin scale and Glascow outcome scale 
at 30 and 90 days were also used for evaluation of these symptoms. Vital signs were monitored 
at 24 hours and were maintained below 185/110mmHg following administration of the drug. 
Clinical laboratory tests were also used to monitor patient status, measuring a complete blood 
cell count, coagulation tests, and fibrinogen and fibrin degradation products at baseline, 6 hours, 
and 24 hours following administration. Noncontrast CT scan were also performed at baseline, 6 
hours and 24 hours, 23 days and 37 days, or sooner is patient showed signs of neurological 
deterioration for assessment of intracranial hemorrhaging, infarct signs and size of infarct10. The 
results of this study can be further explored in the discussion section of this paper.   
 The largest study, in terms of total patients, ever conducted that evaluated the benefits of IV 
thrombolytics in treatment of AIS was the 3rd installment of the International Stroke Trial (IST-
III). IST-III was an open-label, international, multicenter, randomized, controlled trial that 
explored the benefits of tPA within 6hours of symptom onset. A total of 3035 patients from 12 
different countries were enrolled in this trial. Eligible patients had presented with a known time 
of symptom onset and could start of treatment within 6 hours. Patients were also excluded if they 
showed signs of ICH or any structural brain lesions on CT or MRI. Patients were randomized 
upon confirmation of eligibility and the intervention grouped would receive 0.9mg/kg plus 
standard care vs the control being standard care alone, of which the article did specifically 
mention what was included in “standard care”. The total number in each group was intervention 
group, 1515 and control group, 1520. The primary outcomes evaluated patients using the Oxford 
handicap scale, which is essentially identical to the modified Rankin scale 34, of which a 
favorable outcome was measured as a score of 0-2 at 6 months. Secondary outcomes measured 
multiple areas at 18 months following treatment including; overall survival, Oxford handicap 
score, health-related quality of life, overall functioning, and living circumstances 11. Results from 
this trial will be further explored in the discussion section of this paper.  
 The use of thrombolytics as the “gold standard” treatment is essentially based on these trials 
previously discussed. More than 20 years following the NINDS trial, studies have tried to look 
again at the benefits of thrombolytics in the treatment of AIS. Due to the extensive nature of 
adverse effects of thrombolytics and the new emergence of DMT, studies have tried to focus 
more on determining which patient populations could benefit more with less adverse effects 
instead of utilizing thrombolytics on the majority of patients with symptoms of stroke. Due to the 
advancement of technology, these studies have looked more closely at which patient populations 
could benefit from tPA using advanced imaging and will be discussed later in the paper.   
Endovascular therapy  
 Before discussing studies surrounding this approach to endovascular treatment of AIS, this 
paper will provide background information about the procedure itself. Endovascular or intra-
arterial therapy (IAT) is a relatively new treatment approach that was achieved in 2008 and 
refers to a catheter-based approach to physical disruption of a clot, locally injected thrombolytic 
agents, such as tPA, or both in conjunction. arteries 12. The stent-like thrombectomy devices, 
now called stent-retriever, are the primary catheters used for the procedure today 13.  IAT are 
currently only used for large artery occlusion in the basilar, distal carotid, or proximal middle 
cerebral arteries 12. The procedure to disrupt the clot includes two possible techniques; the stent 
retriever technique and the aspiration technique, and can be done under general anesthesia with 
intubation or conscious sedation.  
 The stent retriever technique involves entering the target occluded vessel, most commonly 
beginning at the carotid artery, with a 0.014-inch guidewire and microcatheter between 0.018 
and 0.027 inch followed by a stent retriever device with sizes that can range from 3.0x15mm to 
6.0x30mm depending on which vessel is occluded. The guidewire is pushed through the 
thrombus and the microcatheter is placed distally to the thrombus. Then, the stent retriever 
device is advanced distal to the thrombus where the guidewire and microcatheter are then 
removed, allowing for the stent retriever device to expand and “capture” the thrombus, which 
can be seen on fluoroscopy evidenced by spontaneous return of partial blood flow. After a short 
period of time, the device is pulled back with continuous aspiration and negative pressure to 
prevent further disruption of the clot (Figure 7). Outcome of the procedure is measured by the 
Thrombolysis in Cerebral Infarction (TICI) score, which is repeated until a score of 2b or 3 is 
reached 14. The TICI score measures the response to reperfusion therapy measured by 
angiographic appearance of the occluded vessel. The grading is a scale of 0-3; grade 0, no 
perfusion; grade 1, penetration with minimal perfusion; grade 2, partial perfusion subgrouped 
into A and B which characterized by amount and speed of filling; and grade 3, complete 
perfusion 15. Although this treatment is still new to the AIS world, endovascular therapy has 
shown promising results in the treatment of AIS as well as negative results.  
 The aspiration technique is an alternative technique used for patients undergoing endovascular 
therapy but present with unique situations. These situations include occlusions located in the 
internal carotid artery, middle cerebral artery bifurcation and trifurcation, or hard thrombi 
configuration. This technique begins similarly to the stent retrieval device technique, where the 
catheter is inserted near the occluded vessel. However, unlike the retrieval stent, the guidewire, 
microcatheter and aspiration catheter are placed into the proximal part of the thrombus. The 
thrombus is essentially sucked in through the aspiration catheter, where entrapment of the 
thrombus is indicated by the absence of backflow. The aspiration catheter is then retrieved using 
constant negative pressure to ensure capture of the thrombus avoid loss or breakage of any part 
of the thrombus. Success of the procedure is indicated by a TICI grade of 2 or 3 16(Figure 8).  
 Perhaps the most influential trial regarding thrombectomy in treatment of AIS was the MR 
CLEAN trial conducted in 2015. The trial was a pragmatic, multicenter, randomized, open-label 
trial that consisted of 500 adult patients with clinical signs of AIS. Inclusion criteria included 
symptom onset within 6 hours and signs of ischemic stroke specifically in the anterior 
circulation; distal internal carotid, middle cerebral artery, or anterior cerebral artery, confirmed 
by CTA or MRA. The intervention group would receiver intra-arterial treatment (IAT), 
consisting of either direct mechanical thrombectomy, intra-arterial thrombolysis or a 
combination of both, which was left to the interventionist. IAT dose was given as a maximum 
dose of 90mg of tPA or 1,200,000 IU of urokinase, and the dose was restricted to 30mg or 
400,000 if already given IV tPA, respectively. Mechanical thrombectomy procedures included 
retrievable stent, aspiration, thrombus retraction or wire disruption. The comparison group 
consisted of intravenous tPA alone. Primary outcomes measured the mRS score at 90 days, 
categorized as an “improved excellent outcomes” as a mRS score of 0-1 and “improved 
functional independence” as a mRS score of 0-2. Safety outcomes also measured mortality and 
symptomatic intracerebral hemorrhaging, measured by imaging not specifically mentioned. The 
results of this study can be further explored in the discussion section of this paper.   
 There are several other studies using endovascular therapy that were conducted similarly to the 
MR CLEAN study. EXTEND IA, ESCAPE, SWIFT PRIME and REVASCAT are all separate 
trials published in 2015 that also explored the benefits of endovascular therapy vs tPA alone, 
similar to the MR CLEAN trial. There were only slight differences between these trials and the 
MR CLEAN trials, such as different imaging to screen patients and specified occluded vessels 
for eligible patients. For example, the EXTEND IA trial used CT perfusion to measure for 
salvagable brain tissue and would only trial IAT for patients with ICA or MCA occlusion 18. The 
ESCAPE trial used CTA to screen for specifically proximal MCA occlusion (with or without 
ICA occlusion) and good collateral circulation, indicated by >50% filling of MCA circulation 
territory 19. SWIFT PRIME used “vessel imaging” to confirm occlusion anywhere in the 
proximal anterior intracranial circulation with absence of large vessel ischemic cores 20. 
REVASCAT used any “neuroimaging” to confirm occlusion in proximal anterior circulation and 
selected patients were either ineligible to receive tPA or had not recanalized within 30 minutes of 
IV tPA administration. Another component of this study included interventionalists had to have 
performed at least 60 mechanical thrombectomies in their careers in order to perform the 
operation 21. Unfortunately, all of these trials were stopped early either because of a prespecified 
boundary for stoppage of the trial, lack of efficacy, or equipoise results to the MR CLEAN trial. 
More specific results will be further explored in the discussion section of this paper.    
 Three recent trials explored the benefits of combining IV tPA with mechanical thrombectomy 
vs IV tPA alone for patients with large vessel occlusion. The THRACE trial conducted in 
consisted of a total of 414 patients from 26 different centers in France and were randomized 
based on inclusion criteria of neurological defect with confirmed ischemic findings on either 
CTA or MRA. In order to qualify for IV tPA, patients had to present with a known symptom 
onset within 4 hours, and in order to qualify for the MT, patients had to present within 5 hours of 
symptom onset. Patients received IV tPA at 0.9mg/kg administered as 10% bolus followed by 
the remaining 90% dose given over the next hour, with a maximum dose of 90mg for patients 
>100kg. Primary outcomes were measured by functional independence, defined as a mRS score 
of 0-2 at 90 days 22. The THERAPY trial conducted in 2016 and was essentially the same trial in 
regards to inclusion criteria, intervention vs control groups and primary outcomes. The only 
difference was that THRACE specifically used aspiration mechanical thrombectomy in their 
intervention group (in addition to IV tPA). The results of these trials will be explored in the 
discussion section of the paper.  
 The third study that explored the benefits of combining IV tPA with mechanical 
thrombectomy vs IV tPA alone for patients with large vessel occlusion was the SKIP 
Randomized Clinical trial. This trial was an investigator-initiated, multicenter, randomized, 
open-label, no inferiority clinical trial that evaluated 204 patients in Japan with acute ischemic 
stroke due to large vessel occlusion. Although this trial is very similar to the trials previously 
discussed, this trial wanted to explore if a lower dose of tPA is essentially “needed” in 
combination of mechanical thrombectomy. The author specifically wanted to address whether 
mechanical thrombectomy alone is “non-inferior” to combined intravenous thrombolysis using 
0.6-mg/kg. The eligibility criteria for this study was much more extensive than previous studies; 
aged 18 to 85 years old, acute stroke with findings of ICA or MCA occlusion on CTA or MRA, 
Alberta Stroke Program score of 6 to 10, DWI ASPECTS score of 5-10, an initial NIHSS score 
equal to or greater than 6, and mRS score of 0-6 before symptom onset. The patients must also 
have met eligibility criteria of the “Japanese guidelines for treatment with lower dose of 
0.6mg/kg tPA within 4.5 hours of symptom onset”, which were the exact same as the NINDS 
trial. The intervention group had a total of 101 patients and received mechanical thrombectomy 
alone, where the control group had a total of 103 patients and received a combination of 
mechanical thrombectomy with 0.6mg/kg IV tPA.  The primary outcomes included favorable 
outcome measured by mRS score of <2 on at 90 days 23. The results of this study can be further 
explored in the discussion section of this paper. 
 Three studies conducted in 2013 also explored the efficacy of endovascular therapy compared 
to tPA alone, including one study that directly compared DMT to tPA without combination 
therapy (MR RESCUE). These three studies were SYNTHESIS, IMS 3 and MR RESCUE and 
will be outlined below. 
 The SYNTHESIS trial was a pragmatic, multi-center, randomized, open-label trial that 
consisted of 362 randomly assigned patients to receive either endovascular therapy, IV tPA or a 
combination of both. Eligible patients with a definitive time of onset of symptoms received 
imaging to confirm AIS findings as well as rule out intracranial hemorrhaging. All patients who 
presented within 4.5 hours of symptom received randomization to either IV tPA or endovascular 
therapy, and patients who presented within 6 hours of symptoms were enrolled into the 
intervention group. IV tPA dose was given immediately following randomization at a dose of 
0.9mg/kg administered as 10% bolus followed by the remaining 90% dose given over the next 
hour, with a maximum dose of 90mg. Endovascular therapy consisted of disintegration of the 
thrombus through micro-guidewire, stent retrieval devices, or aspiration technique. Patients in 
the intervention group that showed a neurological deficit, measured using the NIHSS, with no 
corresponding occlusion received IAT tPA into the presumably affected area. The dose was the 
same as IV tPA.  The primary outcome measured mRS score at 90 days, recognizing a favorable 
outcome as a score of 0-1. Safety outcomes measured intracranial hemorrhaging and mortality 24. 
The results of this study can be further explored in the discussion section of this paper.   
 The IMS 3 trial was a multicenter, randomized, open-label trial that evaluated the benefit of 
performing endovascular therapy following administration of tPA. A total of 656 patients were 
randomized in a 2:1, intervention to control, ratio with signs of major cerebral vessel occlusion. 
The criteria for this trial to receive intervention was dependent on whether the patient had a large 
cerebral vessel occlusion, however the eligibility criteria in this trial was majority based on an 
NIHSS score of >10, which indicated a >80% likelihood of a major arterial occlusion on 
subsequent angiography based on the results of a different study conducted 25. Later in the trial, 
amendment 3 to eligibility protocol, and after 284 patients had already enrolled, identification of 
occluded vessels with CTA as allowed to determine eligibility for intervention. All participants 
with a symptom onset within 3 hours would receive the standard dose of tPA on arrival; 
0.9mg/kg administered as 10% bolus followed by the remaining 90% dose given over the next 
hour, with a maximum dose of 90mg for patients >100kg. Randomization would take place 
within 40 minutes after the initiation of the infusion, where patients in the intervention group 
would receive 2/3 of the standard dose and patients in the control group would receive a full 
standard dose of tPA. The intervention group would then confirm with angiography imaging. 
Angiography would have to confirm evidence of treatable occlusion to receive further 
endovascular treatment, which was up to the discretion of the interventionist. Operations 
included thrombectomy, revascularization device, or an endovascular delivery of tPA. The 
primary outcomes included favorable outcome measured by mRS score of <2 on at 90 days. The 
intervention group used the TICI score following procedures 26. The results of this study can be 
further explored in the discussion section of this paper.   
 MR RESCUE was a phase 2, multicenter, randomized, open label trial that evaluated whether 
patterns on imaging could predict therapeutic outcome with different treatment approaches such 
as, in this case, standard care with tPA or mechanical embolectomy. 118 total patients with 
stroke symptom onset within 8 hours were randomized to receive either mechanical 
embolectomy or standard medical care. Eligibility criteria included symptom onset within 8 
hours and an NIHSS score of 6 to 29 (out of a score of 42), and showed signs of large-vessel 
occlusion in the anterior circulation on either CTA or MRA. All patients received either CT or 
MRI at baseline in order for stratification based on the presence of “favorable penumbral 
pattern”, which was defined as a predicted infarct core size of 90mL or less and predicted 
infarcted tissue within the at-risk region was 70% or less. The intervention group was treated 
with all FDA-approved devices at the time including the Merci Retriever, a stent retrieval device, 
Penumbra system, a reperfusion and aspiration device, as well as intra-arterial tPA for “emergent 
use” if revascularization was not achieved within 6 hours after symptom onset. The control 
group received standard care, however the article does not mention the specific dose of tPA. The 
primary outcomes wanted to evaluate specifically if the presence of a favorable penumbral 
pattern would benefit more with mechanical embolectomy as compared to standard of care. 
Primary outcome measurements were mRS score, however the article does not mention time 
frame of measurement. Secondary outcomes measured TICI score at 7 day imaging follow up 
with CR or MRI, and was considered successful reperfusion if there was a reduction of 90% or 
more in the volume of perfusion lesion 27. The results of this study can be further explored in the 
discussion section of this paper.  
Imaging in AIS 
 Imaging is one of the most important modalities providers have to detect ischemic changes of 
the brain in conjunction clinical presentation. The American College of Radiology (ACR) 
continually updates its guidelines through the ACR Appropriateness Criteria regarding imaging 
modalities for patients presenting with acute neurodeficits with suspected stroke, both less than 
and greater than 6 hours since symptom onset. According to these guidelines, the ACR 
Appropriateness Criteria provides evidence-based guidelines to assist referring providers in 
making the most appropriate imaging and management decisions for specific clinical situations. 
The following section will discuss the different imaging modalities used for evaluation of AIS as 
well as common findings seen with different imaging modalities.  
 Rapid evaluation of strokes is necessary to provide quick decision making when managing a 
patient with stroke symptoms. A noncontrast computed tomography (CT) scan is the primary 
imaging modality for the initial evaluation of patients with suspected stroke according to the 
ACR (ACR, 2009). Noncontrast CT scans are primarily used because the scan is quick and since 
blood will be seen as hyperattenuation, or bright white, in acute strokes, signifying a 
concentrated area of blood.   Findings on noncontrast CT scans are also able to help distinguish 
timeframe of ischemic changes and are typically divided into three main stages; acute stroke 
(less than 24 hours), subacute stroke (24 hours to 5 days), and chronic (weeks to months). Other 
terminology used for acute stroke are “early ischemic changes” or “hyper-acute changes”. Acute 
ischemic changes cause intracellular edema and causes loss of normal gray matter and white 
matter interface, termed “differentiation”. It also causes central sulci effacement which is 
representative of a local secondary sign of mass effect on the brain parenchyma, thus displacing 
the cerebrospinal fluid to push the adjacent gyri together 28 (Figure 1) Subacute changes are 
represented by vasogenic edema with greater mass effect, and can be seen as hypoattenuation 
and well-defined margins on CT scans. (Figure 2) However, as time goes on and intracranial 
swelling goes down and small amounts of cortical petechial hemorrhaging occurs, this can 
actually produce a hyperattenuating effect, also known as the “CT fogging phenomenon”. This 
can often be a misleading representation due to the brain tissue often looking “normal” (Figure 
3). Chronic changes can be represented by complete loss of brain tissue and are hypoattenuating 
on CT scans. The damaged necrotic tissue is reabsorbed which results in encephalomalcia, which 
can be described as blurred cortical margins and decreased brain tissue consistency consistent 
with gliosis of adjacent brain tissue (Figure 4). Noncontrast CT scans are also used to rule out 
other etiologies that may present similarly to acute ischemic strokes. Examples of other 
etiologies include intracerebral hemorrhaging, intraparenchymal hematomas, intracerebral 
abscess, and tumors.  
 Once there is confirmed ischemic changes on noncontrast CT scan, the next imaging modality 
typically used is the computer tomography angiogram (CTA). The CTA provides is a minimally 
invasive imaging study that requires a time optimized rapid injection of intravenous contrast at 
the same time as thin-section helical CT images are obtained during the arterial phase. These 
thin-sectional axial CT images enable the viewer a more complete view of the cerebral 
vasculature real time (Figure 5), where the three-dimensional reformations provide an even 
clearer image of the cerebral vessels. This imaging can evaluate the circulation beginning at the 
aortic arch through the entire Circle of Willis, often performed in under 60 seconds.  This 
imaging is effective at identifying specifically where the clot is within the cerebral blood vessels 
in rapid fashion. This is especially important because the advanced imaging gives providers more 
information inside the body in conjunction with the clinical presentation to make the most 
appropriate decisions regarding the management. CTA can also utilize the clot burden score 
(CBS), which is a 10-point scoring system that quantifies the extent of the thrombus within the 
anterior cerebrovascular circulation, specifically looking at the major anterior circulation 
including the middle cerebral artery (M1) and anterior cerebral artery (A1). The scoring system 
works by subtracting two points for a thrombus preventing opacification on CTA in the proximal 
M1, distal M1, or supraclinoid internal carotid artery (ICA) and one point subtracted for a 
thrombus preventing opacification for M2 branches, A1 and infraclinoid internal carotid artery 
(Figure 6). A score of 10 indicates no thrombus where a score of 0 indicates complete 
multisegment vessel occlusion, where a higher score was typically more associated with 
increased odds of independent functional outcomes 29. Different parameters such as symptom 
onset and area of occluded artery, helps providers determine which medical intervention would 
be most beneficial. Furthermore, these parameters can assist interventional neuroradiologists and 
neurosurgeons in planning operations and procedures.   
 Noncontrast magnetic resonance imaging, or standard “MRIs”, are not as favorable for 
detecting acute strokes (<24 hours) as CT scans. MR imaging can take up to an hour to perform 
which is obviously not favorable when treatment of stroke requires rapid protocol, however are 
“usually appropriate” according to the ARC (ACR, 2009). Unfortunately, standard noncontrast 
MRIs are not very good at detecting cytotoxic and intracellular edema, a primary finding in acute 
strokes of less than 24 hours. However, noncontrast MRIs do a good job of detecting vasogenic 
edema. Vasogenic edema is a primary sign in subacute strokes, which are typically greater than 
24 hours. Fluid attenuated inversion recover (FLAIR) is a type of MR imaging sequence that was 
designed to suppress CSF imaging signal, essentially to appear black not interfere with details of 
the brain tissue itself. It is especially useful in detecting subarachnoid hemorrhages, which will 
appear bright white, and is typically used in the initial evaluation of AIS patients if suspected. 
MR diffusion imaging, or diffusion weight images (DWI), is a fascinating way that uses MR 
imaging to detect ischemic changes. DWI can be performed in as little as 10 minutes and works 
by measuring the “weight”, or motion of water molecules within the brain. Uninjured celled will 
distribute equal amounts of water between neuronal cells, but during the cytotoxic injury to these 
neuronal cells during an ischemic event, water accumulates within the injured cells without the 
ability to diffuse out as quickly as healthy cells. According to one study, once a hemorrhagic 
stroke has been ruled out, MR diffusion improves the detection of acute ischemic stroke from 
50% (with CT) to more than 95% 28. In order to specifically detect the area of ischemia, DWI 
uses an apparent diffusion coefficient (ADC) map which essentially confirms the area of 
restricted water diffusion in order to get an accurate diagnosis. During regular DWI imaging, 
areas of “high signal” will appear bright white, but can be misleading from other “high signal” 
fluid such as vasogenic edema. ADC imaging allows providers to recognize areas that are not 
secondary to acute infarct where impacted areas will appear dark with ADC 30 (Figure 7). 
The shift from “time is brain” to “imaging is brain”  
 One of the most common sayings in medicine is that “we should not treat all patients the 
same”, but this could not be truer when it comes to the management of acute stroke patients. It is 
becoming clearer to providers and researchers alike that imaging may provide a better idea of 
which reperfusion therapy may be more beneficial for different patient presentations. Imaging 
has recently become a primary focus in clinical trials when trying to determine the most effective 
therapy in the treatment of AIS, especially in more recent thrombolytic clinical trials. 
Incorporation of advanced imaging to determine what treatment works for patients with 
salvageable brain tissue may allow for better clinical decisions making while decreasing the 
adverse effects of chosen treatments.  More recent research is trying to answer these questions 
and will be discussed within this section of the paper.  
 The WAKEUP trial was a multicenter, randomized, double-blind placebo-controlled trial 
conducted in 2018 that evaluated whether MRI guided IV thrombolysis could be beneficial for 
patients with an unknown symptom onset, such as waking up from sleep with stroke symptoms 
or 4.5 hours since they were last seen well-appearing in health, such as symptoms of aphasia or 
confusion.  Eligibility of the study included patients 18 to 80 years old who had been able to 
carry out activities of daily living independently before their stroke. The study used two different 
imaging modalities within the MRA to determine eligibility for the study, the diffusion weighted 
imaging (DWI) and standard window settings on fluid-attenuated inversion recover (FLAIR). 
Eligible patients had findings of an acute ischemic lesion on DWI but no parenchymal hyper 
intensity on FLAIR and were selected upon the investigator’s discretion. The chosen imaging 
was due to the suspected stroke occurring approximately in the last 4.5 hours. Eligible patients 
would then receive 0.9mg/kg of alteplase (rtPA), administered as 10% bolus followed by the 
remaining 90% dose given over the next hour, where the intervention group was compared with 
a placebo. A total of 503 were patients enrolled in the study, where 254 patients randomly 
received the rtPA and 249 received placebo. Excluded patients included patients undergoing 
planned thrombectomy operation, intracranial hemorrhaging on MRI, lesions greater than 1/3 of 
the territory of the MCA, and contraindications to alteplase. Primary outcomes measured were 
measured as “favorable clinical outcomes”, measured by a score of 0 to 1 on the modified 
Rankin scale. Secondary outcomes also measured efficacy based on combined scores of mRS 
and NIHSS, including a mRS score of 0 with NIHSS score <7, a mRS score of 0 to 1 with 
NIHSS score of 8 to 14, and mRS score of 0 to 2 with NIHSS score of >14.  Secondary 
outcomes also included a global outcome score at 90 days measured with four scales; mRS, 
NIHSS, Barthel Index, and Glasgow Outcome Scale. A “good outcome” consisted of a mRS and 
NIHSS score of 0 to 1, a Barthel Index score of 95 to 100, and an overall Glascow Outcome 
Scale score. Clinical assessments included the recording of demographic information, medical 
history including concurrent medications, laboratory values, scores on the NIHSS scale and 
modified Rankin scale, and assessment of adverse effects. A standard brain MRI was also 
included in clinical assessment to monitor for ICH and infarct volume, measured at 22 to 36 
hours after randomization. The primary safety end points evaluated were death and “poor 
outcomes”, which were measured by a mRS score of 4 to 6 at 90 days. Secondary safety end 
points utilized the aforementioned clinical assessment MRI imaging at 22 to 36 hours after 
randomization to evaluate for symptomatic ICH and incidence of parenchymal hematoma type 2, 
and were evaluated by an independent ventral safety-adjudication committee by members 
unaware of the trial 31. This study essentially tried to determine if there were specific timing 
parameters, determined by ischemic changes on MRI, that could help determine beneficial 
administration of thrombolytics in AIS patients after the standard of care time frame. 
Unfortunately, the study was stopped early due to cessation of funding, however the results of 
this study can be further explored in the discussion section of this paper.   
 More recent studies have tried to examine whether imaging can help determine if 
administration of tPA is beneficial for patients after 4.5 hours, the standard of care timeframe for 
treatment of AIS with tPA. The primary study was the fourth rendition of the European 
Cooperative Acute Stroke Study (ECASS), labeled as the ECASS4-EXTEND trial, which 
wanted to further explore if imaging could help determine if tPA is beneficial for patients after 
4.5 hours of symptom onset. The study was an investigator driven, phase 3, randomized, multi-
center, double blind, placebo-controlled study. The patient eligibility included patients 
presenting with AIS symptom onset of 4.5 to 9 hours or upon waking up without definitive 
symptom onset timeframe with acute neurological deficit, quantified as a 4-26 NIHSS score, and 
pre-stroke mRS score of 0-1. Eligible patients then would undergo MRI scanning. Imaging 
eligibility criteria for randomized treatment then included findings of infarct core volume of 
<100mL, perfusion lesion characterized as an infarct core mismatch ratio >1.2, and perfusion 
lesion minimum volume of 20mL. The intervention group would receive 0.9 mg/kg tPA with a 
10% IV bolus followed by the remaining through infusion over 1 hour. Primary outcomes 
measured as favorable outcomes included a mRS score of 0 to 1 at 90 days following treatment. 
Secondary and tertiary outcomes included disability at day 90, NIHSS reduction of 11 or more 
points, recanalization at 24 hours post stroke, depression and life quality.  Safety outcomes 
included symptomatic intracranial hemorrhaging and mortality 32. The results of this study can be 
further explored in the discussion section of this paper.   
 Methods   
 The data discussed in this research paper came from an extensive search using credible 
databases such as PubMed, Google Scholar, New England Journal of Medicine (NEJM) and the 
National Center for Biotechnology Information (NCBI). Many of these databases directed to 
studies conducted by credible Search terms for relevant vocabulary and information about 
subjects included “tPA”, “mechanical thrombectomy”, “stroke standard of care”, “endovascular 
therapy”, “modified Rankin scale”, and “stroke imaging”. Background information was also 
explored using credible medical websites such as REBELEM.com. This website is an emergency 
medicine-based blog that includes frequent reviews of emergency medicine related clinical trials 
as well as a podcast that includes discussion points about clinical trials, unique cases in the 
emergency department, or other general discussion about emergency medicine topics.  
Discussion   
 The results of the previously discussed trials will be discussed during this section of the paper. 
The structure of this discussion will focus on discussing positive versus negative studies, defined 
as studies showing a benefit vs studies showing no benefit or lacks evidence to support benefit. 
Positive and negative studies will be grouped together accordingly. The majority of the primary 
outcomes from each study evaluated a mRS score at 90 days and will be the primary focus of 
these discussion results, however additional or different primary outcomes will be mentioned if 
applicable to the study. The main topic of this paper is trying to compare and contrast each 
treatment approach, either mechanical thrombectomy or standard care with tPA, to determine 
which may be more beneficial in decreasing long-term morbidity in patients following AIS. The 
results from these articles will be used to compare and contrast these different therapeutic 
approaches in order to determine if any one therapy is more beneficial for reducing long-term 
morbidity.  
 Before exploring the results of the previously discussed clinical trials, it would be beneficial to 
define the different outcome measurement scores that these studies use. The Barthel index is a 
reliable scoring system that measures the ability to perform activities of daily living (ADL) such 
as eating, bathing, grooming, dressing, bowel control, bladder control, toilet use, bed to chair and 
back transfers, mobility and stairs. Scores are variable with each ADL but in summary 
independent receives a full score of 10, assistance needed receives a 5, and dependent receives a 
0. All scores added up will determine the overall score, where a score of 100 is considered 
completely independent 33. The modified Rankin scale is an overall assessment of function in 
which a score of 0 indicates the absence of symptoms, score of 1-5 indicate severity of disability, 
and a score of 6 indicates death 34. The Glasgow outcome scale a global assessment of function 
in which a score of 1 indicates a good recovery; a score of 2 indicates moderate disability; a 
score of 3 indicates severe disability; a score of 4 indicates survival but in a vegetative state; and 
a score of 5 indicates death 35. The NIHSS was specifically developed for the NINDS trial and is 
a serial measure of neurologic deficit that uses a 42-point scale that quantifies neurologic deficits 
into 11 categories. NIHSS determines the patients level on consciousness and attention by asking 
the patient questions and asking them to perform simple tasks. For example, asking the patient 
their own age and what month it is; answering both questions right would be 2 points, one 
question right is 1 point, and neither is 0 points. Further exploration of motor and sensory 
function through extensive tests such as extraocular eye movement, “squeezing hands”, visual 
fields, facial palsy, arm motor drift, leg motor drift, ataxia, overall sensation, language/aphasia, 
and dysarthria 36. The global test statistic is a proposed equation that allows researchers to 
evaluate several different performance categories or measurement tools, and make overall 
statements based off those components of related importance 37. 
tPA results 
 There have been two studies in the last 30 years that showed positive benefit for tPA use in the 
treatment of AIS, the NINDS-II and ECASS-III trials. NINDS-I showed no significant 
improvement, however it’s primary outcome was measured with NIHSS score at 90 days. 
NINDS-II used the previously discussed four outcome scales and did show significant 
improvement in all four categories at 90 days. Both parts of the studies were combined together 
and evaluated all four outcome measurements, both at 0-90 minutes, 91-180 minutes, and 0-180 
minutes. For the specific purpose of this discussion, the NINDS-I did not show significant 
improvement of mRS score at 90 days in patients receiving tPA (Figure 9). The NINDS-II trial 
showed favorable outcomes in 39% of patients receiving tPA versus 26% in patients receiving 
placebo on mRS score at 90 days, with an odds ratio of 1.7 (Figure 10). The ECASS-III trial 
evaluated a different timeframe for administration of tPA that was previously discussed, the 
timeframe specifically being between 3 and 4.5 hours. ECASS-III showed favorable outcomes in 
52.4% in patients receiving tPA vs 45.2% in patients receiving placebo, with an odds ratio of 
1.34. 
 The following studies have been deemed as negative trials, including ECASS-1, ECASS-II, 
ATLANTIS, and IST-III. ECASS-1, however, did show a significant improvement in mRS at 90 
days, resulting in favorable outcomes of 35.8% of patients receiving tPA versus 22.3% of 
patients receiving placebo (Figure 12). ECASS-2 results showed favorable mRS scores in 40.3% 
of patients receiving tPA versus 33.6% of patients receiving placebo, resulting in statistically 
insignificant findings. The ATLANTIS trial(s) results showed favorable mRS scores in 34% of 
patients receiving tPA versus 32% of patients receiving placebo, resulting in statistically 
insignificant findings. The IST-III trial results showed favorable OHS scores at 6 months in 37% 
of patients receiving tPA versus 35% of patients receiving placebo, resulting in statistically 
insignificant findings. 
 The other two studies evaluated the benefits of using tPA in conjunction with more advanced 
imaging modalities; WAKE UP and EXTEND. The WAKE UP trial showed favorable mRS 
scores in 53.3%% of patients receiving tPA versus 41.8% of patients receiving placebo. 
Unfortunately, the trial was stopped early due to cessation of funding after the enrollment of 503 
patients of the anticipated 800 patients. The EXTEND trial showed favorable mRS scores in 
35% of patients receiving tPA versus 29% of patients receiving placebo. Unfortunately, this trial 
was also stopped due to cessation of funding after the enrollment of 225 patients of the 
anticipated 310 patients.  
 Overall, using mRS data from all the studies, intervention with tPA produced a 36.65% benefit 
compared to 32.57% benefit with control (Table 1). These statistics argue that treatment with 
tPA is statistically insignificant as compared to placebo. These statistics can conclude that tPA 
may have an advantage in treatment of AIS, however more studies need to be done to evaluate 
for efficacy.  
Endovascular results 
The following 3 studies are slightly different than the subsequent studies in that imaging 
(CTA or MRA) was not done to definitively prove proximal occlusion when patients presented 
with symptoms of stroke. Also, since these trials were older, the subsequent trials used more 
technologically advanced stent retrievers in their trials. SYNTHESIS showed favorable mRS 
scores in 30.4% of patients receiving endovascular therapy versus 34.8% of patients receiving 
systemic IV tPA alone, showing statistically insignificant results.  The IMS-III trial showed 
favorable mRS scores in 40.8% of patients receiving endovascular therapy versus 38.7% of 
patients receiving systemic IV tPA alone. However, this trial was stopped early due to futility of 
the study. MR RESCUE evaluated a mean mRS score at 90 days which resulted in mean score of 
3.9 for both the embolectomy group and standard care with tPA group, showing statistically 
insignificant results.   
The following trials did require inclusion criteria of proximal vessel occlusion seen on 
CTA or MRA, essentially utilizing more advanced technology that the previously discussed trials 
did not have access to. MR CLEAN showed favorable mRS scores in 44.2% of patients in the 
endovascular therapy group versus 25.1% of patients receiving standard of care with tPA. Of 
note, 89% of all patients were treated with IV tPA before randomization.  EXTEND IA showed 
favorable mRS scores in 71% of patients in the endovascular therapy group versus 40% of 
patients receiving standard of care with tPA. ESCAPE showed favorable mRS scores in 53% of 
patients in the endovascular therapy group versus 29.3% of patients receiving standard of care 
with tPA. However, this trial was stopped early due to efficacy. SWIFT PRIME showed 
favorable mRS scores in 60% of patients in the endovascular therapy group versus 35% of 
patients receiving standard of care with tPA. However, this trial was stopped early at 196 
patients. Of note, the trial was also funded by Covidien, the maker of the Solitaire retriever 
which could indicate bias.  REVASCAT showed favorable mRS scores in 43.7% of patients in 
the endovascular therapy group versus 28.2% of patients receiving standard of care with tPA. 
Unfortunately, this trial was also stopped early at 206 patients instated of the anticipated 690 
patients, again minimizing magnitude of the results. Of note, this study was also funded by 
Covidien as well. THRACE showed favorable mRS scores in 53% of patients in the combined 
endovascular therapy and tPA group versus 42% of patients receiving standard of care with tPA. 
Unfortunately, this study was also stopped early, resulting in a total of 414 patients. Of note, 
mRS scores were estimated by neurologists that were not blinded to treatment arms. THERAPY 
showed favorable mRS scores in 38% of patients in the endovascular therapy group versus 
30%% of patients receiving standard of care with tPA, which was statistically insignificant. This 
trial was also stopped early and thus impacts power of the study results. SKIP trial favorable 
mRS scores in 57.3% of patients in the combination endovascular and tPA group versus 59.4% 
of patients receiving standard of care with tPA.  
Overall, using mRS data from all the studies, intervention with endovascular treatment 
produced a 43.58%% benefit compared to 32.59% benefit with control (Table 2). These statistics 
argue that treatment with endovascular remedies is statistically significant and could be debated 
that it is a better option as compared to placebo. These statistics can conclude that endovascular 
therapy may have an advantage in treatment of AIS, however more studies need to be done to 
evaluate for efficacy.  
Conclusion 
 The debate of treatment of AIS still remains strong today. There have been many important 
studies that have tried to evaluate the best approach to treatment of AIS, however, based on the 
studies discussed in this paper and the scientific community overall. Although many of the 
studies discussed show promising results, the data to support an efficacious treatment still 
remains unclear. 
 The use of tPA has long been a debated subject in the treatment of AIS and after doing 
extensive research on this drug, it is easy to see why. The studies discussed in this paper do not 
show extensive evidence as to legitimate efficacy for treatment of AIS. It is also hard not to 
analyze these studies to see that there could be many confounding interests that potentially leave 
room for bias in writing the results. However, although tPA has not distinctively proven its 
efficacy, it is still the standard treatment approach to stroke. 
 Endovascular therapy is a promising new way for treatment of stroke, however, it is difficult to 
determine if it is, in fact, superior to tPA. The studies discussed in this paper are also very much 
susceptible to bias after further analyzing the results. One obvious confounder to these studies is 
that several studies were stopped early, drastically impacting the magnitude of benefit for 
patients receiving endovascular therapy. More studies need to be done and fully completed in 
order to determine if endovascular therapy is as beneficial as these studies result in.  
 There is a large gap in the years of publication for the studies discussed in this paper, however, 
the use of advanced imaging has made an impact on researching this topic at greater detail. 
Rather than administering tPA or performing endovascular therapy on patients with symptoms of 
stroke, researchers are trying to use technological advances in imaging modalities to determine 
who may benefit for either therapy. Moving forward, focusing on these confounders in future 
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Axial noncontrast computer tomography shows hypoattenuating foci through the left sided white 




   
Figure 2: 
Axial noncontrast computer tomography 24 hours after symptom onset showing a hypodense 





Figure 3:  
Axial noncontrast computer tomography taken at 36 hours (left image) and 18 days (right 
image). Left image shows occipital hypodensities consistent with infarction, where the right 







Axial noncontrast computer tomography demonstrating chronic ischemic stroke changes in the 













Figure demonstrating the clot burden score, including the regions within the circulation with its 
corresponding subtracted value. From proximal to distal two point subtractions; proximal M1 
middle cerebral artery (MCA), and distal M1 MCA. supraclinodial ICA, From proximal to distal 
one point subtractions; M2 middle cerebral artery (MCA), anterior cerebral artery (A1), and 






















MR diffusion showing a right MCA occlusion. Box A) DWI imaging shows  area with increased 
signal intensity consistent with area of right MCA occlusion. Box B) ADC imaging shows area 






A) Angiography showing an acute middle cerebral artery occlusion with placement of stent 
retriever device. The distal end of the stent retrieval device (white arrow); the thrombus is 
pressed to the vessel wall (black arrows) with spontaneous partial flow restoration. B) Successful 
recanalization of the artery as evidence by complete restoration of blood flow. C) Stent retrieval 








Endovascular thrombectomy with the aspiration technique in acute ischemic stroke. A) CT 
angiography showing acute occlusion of the distal middle cerebral artery (white arrow), B) 
placement of an aspiration catheter proximally to thrombus (white arrow). C and D) Parts of 
thrombus material within the aspiration tube following retrieval (white arrows). E) CT 















Table comparing results of mRS score among studies evaluating efficacy of tPA as 



















Table comparing results of mRS score among studies evaluating efficacy of endovascular 
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